Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| And in conclusion, the early selling season activity gives us confidence that the macro trends driving the high demand for family building benefits combined with our position as the leader in the space position us well to sustain our growth trajectory |
| Adjusted EBITDA margin on incremental revenue, which most clearly highlights our rate of margin capture as we grow and has proven to be useful as a forward indicator of where the overall business is moving, was 20.3% in 2023, further demonstrating the leverage that we've continued to achieve on the most recent cohort of revenue |
| As important as those financial measures of success are, we're equally pleased with what we've achieved operationally |
| This experience ideally positions us for success as we enter 2024 with a more comprehensive set of services |
| Pharmacy revenue increased 39% in the fourth quarter to $98.6 million and grew 49% over the full-year to $412 million |
| Aided by the quality and reach of that network and the ways in which we collaborate with them, we continue to achieve, for the eight straight year, the industry-leading clinical outcomes in fertility care |
| And while it's too soon to offer any quantitative commentary, the early activity that we're seeing thus far is very positive |
| The improvement in both the quarter and the year is primarily due to efficiencies that we continue to realize in our back office operations even as we rapidly expand the business |
| And we've done so while routinely achieving NPS scores in the 80s, an exceptional achievement for any industry, let alone healthcare |
| As a mission-driven company, where everything we do is about empowering people to successfully meet the milestones in their lives through evidence-based solutions, we're perhaps proudest of our sustained clinical success, because we understand how those outcomes aren't just numbers on a page, but tangible life changing results for people every day |
| At the midpoints of this guidance, we are expecting to see the continued expansion of our margins in 2024, with adjusted EBITDA margin incremental revenue of 19.4% |
| This is our highest quarterly total ever and a 24% increase from the fourth quarter of 2022 |
| You've seen that reflected in the strong member engagement metrics that we've reported to you in 2023 |
| So I think, that's a pretty good financial picture given the amount of investment that we are doing to expand our product portfolio |
| With our strong topline growth and the operating efficiencies that we realized, adjusted EBITDA, both in dollars as well as in margin, increased significantly in both the quarter and the year |
| The 21.9% gross margin in 2023 was a 60 basis point increase over the prior year, reflecting the ongoing efficiencies that we've realized in the delivery of our care management services, which were only partially offset by the impact of our previously disclosed cost containment efforts that were shared with our clients |
| With this strong result, we've more than doubled our revenue over the past two years and achieved a tenfold increase over the past five years, which further attest to the substantial size of our market opportunity as well as our success in executing against our go-to-market strategies |
| These ranges reflect how 2024 will be another year of both strong topline growth and continued margin expansion |
| First, demand for fertility benefits is stronger than ever, particularly among the millennials who are in the prime of their family building years |
| Employers increasingly realize that in doing so, they're not only enhancing the efficiency of their recruitment and retention efforts, they're also meaningfully improving workforce productivity |
| It's the overall business and the overall revenue growth contributes to the overall margin expansion |
| And lastly, by leveraging our proven strengths in patient education and support, evidence-based care pathways, network management and outcomes measurement, Progyny continues to successfully differentiate itself in the market by raising the bar for what employers should expect from their benefit providers |
| With the momentum we continue to see for family building services generally and the energy behind our more comprehensive end-to-end solution, we are excited for the year ahead |
| 2023 was another exceptional year for Progyny, a year in which we achieved record levels of revenue, which grew 38%, profitability with a 17.2%, adjusted EBITDA margin and operating cash flow generating nearly $190 million or more than twice what we delivered in 2022 |
| And given the caliber of the companies that we're both partnering with and seeing in our active pipeline, it's become even more evident that Progyny is the provider of choice for fertility solutions amongst the best known and most successful companies in the world |
| Our full-year operating cash flow was our highest ever at $189 million more than double the $80 million that was generated in 2022 and reflects our higher profitability as well as the previously disclosed impact from an amended agreement with a pharmacy partner, which took effect midway through the year |
| In short, we've entered 2024 with considerable momentum, which comes on the heels of our last three selling seasons, which were the most productive in our history |
| That's why Progyny is so uniquely positioned to expand our already industry-leading platform into other areas that further support life's other key milestones |
| For the full-year, ART cycles grew more than 36%, reflecting the continued high rate of demand that we see for fertility care |
| Because of our proven history of delivering real and sustained value in family building services, we enjoy a sizable advantage as our clients will often proactively share with us the gaps they're looking to address across other areas of healthcare, particularly with respect to patient access, member experience and cost efficiency |
| Statement |
|---|
| And although our Q4 guidance reflected the typical decline in member activity due to the holidays and clinic closures for routine cleaning and maintenance, the actual decline in December was slightly more than what we had anticipated, which is why revenue ended up closer to the midpoint of our Q4 range |
| And while overall utilization levels are in-line with last year, as at this point in the quarter, there was a brief shift in treatment mix at the start of the year, which we estimate resulted in an approximately $15 million headwind on revenue in the quarter from what we normally would expect and which we've reflected in our guidance for the first quarter |
| Our history is that in general, it's been coming down a little bit each year for a couple of reasons |
| It was a Supreme Court ruling on a case that then had an impact and concern around clinics in the state practicing when they're do you create a normal practice more than one embryo when they're doing IVF, right |
| I wanted to ask a little bit about the pharmacy benefit because we are hearing a lot of concerns because of the election year around what this means for PBM |
| Second, family building and women's health benefits have never been more relevant or more timely with employers, particularly as they look to modernize the coverage they're providing in order to better support their employees' needs |
| That said, there have been periods and again, the most pronounced one was summer of ‘21, right, where we had blips or anomalies or aberrations or whatever you want to call them, where treatment mix was a little off for a short period of time, but then reverted back to normal |
| Wade got overturned, where there was concern that fertility or IVF can inadvertently get caught up in the anti-abortion laws that were coming out, and then that didn't happen |
| But there's nothing out there that I'm seeing or hearing about as I talk to the attorneys that causes me concern relative to an impact, economically to our model |
| But having something like this happening at the beginning of the year, little surprising |
| For revenue, we are projecting between $285 million to $292 million in the first quarter, which contemplates the $15 million headwind in treatment mix shift that, Pete, described to you a little bit earlier |
| That's going to contribute to an average lower medical and overall revenue per cycle |
| Again, early in the year to make too many predictions around how that will materialize |
| So you mentioned that your market share right now is pretty low in the mid-single digits |
| What was the other part of your question? Mark Livingston I think the second part was related to competition during sales |
| But since we don't guide margin either, I think it's premature to sort of start commenting on margin expectations |
| Actual results may differ materially from those contained in or implied by these forward-looking statements due to risks and uncertainties associated with our business as well as other important factors |
| First, what is the related EBITDA headwind for this $15 million revenue impact? And how is this $15 million revenue impact split between Medical and Progyny Rx? And the second question for that was that, was this treatment mix shift across the board or was there particular geography or industry you saw this concentrated? The reason I'm asking is because I know, Pete, you're trying to compare this with summer of 2021, but back then you attributed that to possibility of seasonality as people taking summer vacation |
| Just one on competition |
Please consider a small donation if you think this website provides you with relevant information